Jump to content

Trius Therapeutics

Add links
From Wikipedia, the free encyclopedia

Trius Therapeutics (Nasdaq: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics.[1]

Business profile

[edit]

The lead compound from Trius, tedizolid phosphate (formerly torezolid phosphate, TR-701), successfully completed its first Phase 3 clinical trial (ESTABLISH 1) in acute skin and skin structure infections (ABSSSI).[2] It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).[3] The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint.[4] In the ESTABLISH 1 Study, 200 mg of Tedizolid given for a short course of therapy (six days) was shown to be safe, well tolerated and was as effective as the traditional length of therapy with linezolid (600 mg for ten days).[5] Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects.[6]

Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013.[7]

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

The firm was acquired by Cubist Pharmaceuticals at the end of July 2013 in a deal worth $1.6 billion. This fee also included the purchase of Optimer Pharmaceuticals.[8]

Funding

[edit]

In February 2007 Trius was formed (formerly Rx3) in conjunction with a Series A financing.[9] Trius completed an initial public offering in August 2010, raising $50 million.[10] Its stock was added to the NASDAQ Biotechnology Index in 2012.[11]

Partnerships and Government Contracts

[edit]

In 2008 the company received a $28 million contract from the National Institute of Allergy and Infectious Diseases a component of the National Institutes of Health, to develop antibiotics against gram-negative infections. The work included a collaboration with the Lawrence Livermore National Laboratory to help identify antibiotics against gram-negative infections and bioterrorism.[12] Trius was awarded a contract by Lawrence Livermore National Laboratory in 2011 for $3 million.[13] In 2011 Bayer acquired the exclusive rights to Trius' antibiotic tedizolid in certain areas in Asia, Africa, the Middle East, and Latin America.[14] The deal was reported as being worth $94 million.[15]

Employees

[edit]

Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn.[16] Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson,[17] and Chief Development Officer Ken Bartizal.[18] The Chairman of the Board is David Kabakoff.[19] The company today has 83 full-time employees.[20]

References

[edit]
  1. ^ "Trius Therapeutics - About". Triusrx.com. Retrieved 26 July 2012.
  2. ^ "An Investment Update on Trius Therapeutics' Tedizolid (NYSE:MRK) | Seeking Alpha".
  3. ^ "Market Close Report: NASDAQ Composite index closes at 3,807.75 up 33.41 points". www.nasdaq.com. Nasdaq. October 4, 2013. Archived from the original on October 5, 2013. Retrieved 28 May 2023.
  4. ^ "An Investment Update on Trius Therapeutics' Tedizolid (NYSE:MRK) | Seeking Alpha".
  5. ^ "Trius shares surge as antibiotic matches Zyvox in pivotal PhIII". 19 December 2011.
  6. ^ "Trius Therapeutics' Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)". smithonstocks.com. Archived from the original on September 9, 2012. Retrieved 28 May 2023.
  7. ^ Darcé, Keith (31 October 2011). "Trius grows as lead antibiotic moves forward". San Diego Union-Tribune. Retrieved 5 September 2012.
  8. ^ Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
  9. ^ "Emerging Drug Developer: Trius Therapeutics". 28 March 2008.
  10. ^ Scholer, Kristen; Spears, Lee (3 August 2010). "Trius Therapeutics Initial Offer Raises $50 Million". Bloomberg.
  11. ^ "Semi-Annual Changes to the NASDAQ Biotechnology Index". MarketWatch. Retrieved 27 July 2012.
  12. ^ Timmermeyer, Luke (22 October 2008). "Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics". Xconomy. Retrieved 5 September 2012.
  13. ^ "Trius Therapeutics, Inc. Secures Third Government Contract To Develop Antibiotics". www.reuters.com. Reuters. 15 Apr 2011. Archived from the original on 2012-04-20. Retrieved 28 May 2023.
  14. ^ Conover, Damien (3 September 2012). "Premium Articles 5 Big Pharma Opportunities in Emerging Markets". Morning Start. Retrieved 5 September 2012.
  15. ^ Darcé, Keith (27 July 2012). "Trius signs $94 million licensing deal for lead antibiotic". San Diego Union-Tribune. Retrieved 5 September 2012.
  16. ^ "Trius Therapeutics Inc". Bloomberg News. Retrieved 5 September 2012.
  17. ^ "Form 10-K".
  18. ^ "Form 10-K".
  19. ^ "Trius Therapeutics, Inc. Executives". Hoover's. Retrieved 5 September 2012.
  20. ^ "Company Overview of Trius Therapeutics, Inc". Businessweek. Archived from the original on July 31, 2009. Retrieved 5 September 2012.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Trius_Therapeutics&oldid=1250168793"